New drug QCZ484 tested for safety in first human study
NCT ID NCT06905327
First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tested the safety of a single dose of QCZ484 in 56 healthy adults and people with mild hypertension. Participants received either the drug or a placebo, and researchers monitored side effects and lab results. The goal was to see if the drug is safe enough for further testing, not to treat the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Herston, Queensland, 4006, Australia
-
Novartis Investigative Site
Morayfield, Queensland, 4506, Australia
-
Novartis Investigative Site
Adelaide, 5000, Australia
-
Novartis Investigative Site
Auckland, 0622, New Zealand
Conditions
Explore the condition pages connected to this study.